Diabetic nephropathy - A review of the natural history, burden, risk factors and treatment

Journal of the National Medical Association

Volumn 96, Issue 11, 2004, Pages 1445-1454

  Ayodele, Olugbenga E ^a   Alebiosu, C Olutayo ^b,d   Salako, Babatunde L ^c  

^a LADOKE AKINTOLA UNIVERSITY OF TECHNOLOGY   (Nigeria)

^b OLABISI ONABANJO UNIVERSITY   (Nigeria)

^c UNIVERSITY OF IBADAN   (Nigeria)

^d Dugbe General Post Office   (Nigeria)

Author keywords

Burden; Diabetic nephropathy; Risk factors; Treatment

Indexed keywords

PROTEIN;

AGE; DIABETIC NEPHROPATHY; DISEASE COURSE; DYSLIPIDEMIA; GENETIC SUSCEPTIBILITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEIN DIET; RACE DIFFERENCE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING; ULTRAFILTRATION;

AGE FACTORS; ALBUMINURIA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPERTENSION; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 8344244535     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Reeves WB, Andreoli TE. Transforming growth factor b contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA. 2000;97:7667-7669.
2. Alebiosu CO, Kadiri S, Akang EEU. Clinicopathological study of Diabetic Nephropathy based on Renal Biopsy. Diabetes International. 2002;12:66-69.
3. Kimmestiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Path. 1936;12:83-97.
4. Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes. Kidney Int. 1981;19:410-415.
5. Hostetter TH, Rennke GH, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med. 1982;72:375-380.
6. Mongessen CE. Renal function changes in diabetes. Diabetes. 1976;15 (Suppl 2):872-879.
7. Reddi AS, Camerini-Davalos. Diabetic nephropathy: an update. Arch Intern Med. 1990;150:31-43.
8. American Diabetes Association. Diabetic Nephropathy (Position Statement). Diabetes Care. 2002;25(Suppl 1):S85-S89.
9. Remmuzi G, Schiepatti A, Ruggenenti P. Nephropathy in patients with type-2 diabetes. NEJM. 2002;346:1145-1151.
10. Ritz E, Orth SR. Nephropathy in patients with type-2 diabetes mellitus. NEJM. 1999;341:1127-1133.
11. Renal Data System. USRDS 2000 Annual Data Report Bethesda, MD. National Institute of Diabetes and Digestive and Kidney Diseases.
12. European Dialysis and Transplantation Association. Report on management of renal failure in Europe, XXVI, 1995. Nephrol Dial Transplant. 1996;11 (Suppl 7):1-31.
13. Kurokawa K, Nangaku M, Saito A, et al. Current issues and future perspectives of chronic renal failure. J Am Soc Nephrol. 2002;13:S3-S6.
14. King H, Aubert R, Herman H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care. 1997;21:1414-1431.
15. Ritz E, Stefanski A. Diabetic nephropathy in type-2 diabetes. Am J Kidney Dis. 1996;27:167-194.
16. Akinsola W, Odesanmi WO, Ogunniyi JO, et al. Diseases causing chronic renal failure in Nigerians - a prospective study of 100 cases. Afr J Med Med Sci. 1989;18:131-135.
17. Salako BL, Ayodele OE, Kadiri S, et al. Prevalence of hepatitis B and C viruses in predialysis patients with chronic renal failure. Afr J Med Med Sci. 2002;31:311-314.
18. Bosseri S, Beshyah SA. Characteristics of diabetic patients with endstage renal failure on chronic hemodialysis in Tripoli, Libya. Diabetes Int. 2001;11:19-21.
19. Abboud OL, Osman EM, Musa AR. The etiology of chronic renal failure in adult Sudanese patients. Ann Trop Med Parasitol. 1989;83:411-414.
20. Abdurrhim E, Zonaghi K, Hedri, et al. Renal replacement therapy for diabetic end-stage renal disease, experience of a Tunisian hospital center. Diabetes Metab. 2001;27:584-590.
21. United States Renal Data System. Excepts from U.S. Renal Data System 2001. Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2001:38(Suppl 3):S7-S195.
22. Koch M, Kurtkuhn B, Grabense B, et al. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialyzed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant. 1997;12:2603-2611.
23. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type-2 diabetes and nondiabetic subjects with and without previous myocardial infarction. NEJM. 1998;339:229-234.
24. Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745-753.
25. Gill GV, Hurdle KR, Rolfe M. Mortality and outcome of insulin-dependent diabetes in Soweto, South Africa. Diabetic Medicine, 1995;18:971-974.
26. Ahmed AM, Ahmed NH, Abdella ME. Pattern of hospital mortality among diabetic patients in Sudan. Practical Diabetes Int. 2000;17:41-43.
27. Loon NR. Diabetic kidney disease; preventing dialysis and transplantation. Clinical Diabetes. 2003;21:55-62.
28. Krowleski AS. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int. 1999;55:1582-1596.
29. Pettitt DJ, Saad MF, Bennett PH, et al. Familial predisposition to renal disease in two generations of Pima Indians with type-2 (noninsulin-dependent) diabetes mellitus. Diabetologia. 1990;33:438-443.
30. Gall M-A, Hougaard P, Borch-Johnsen K, et al. Risk factors for development of incipient and overt diabetic nephropathy in patients with noninsulin-dependent diabetes mellitus: prospective observational study. BMJ. 1997;314:783-788.
31. Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type-2: effect of ACE inhibitors. Kidney Int. 1995;47:907-910.
32. Hovind P, Rossing P, Tarnow L, et al. Progression of diabetic nephropathy. Kidney Int. 2001;59:702-709.
33. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998;352:213-219.
34. Pugh JA, Stern MP, Haffner SM, et al. Excess incidence of treatment of end-stage renal disease in Mexican Americans. Am J Epidemiol. 1998;127:135-144.
35. Brancati FL, Whittle JC, Whelton PK, et al. The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors JAMA 1992;268:3079-3084.
36. Seaquist ER, Goetz FC, Rich S, et al. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989;320:1161-1165.
37. Jeffers BW, Estacio RO, Raynolds MV, et al. Angiotensin-converting enzyme gene polymorphism in noninsulin-dependent diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int. 1997;52:473-477.
38. Kuramoto N, Lizuka T, Ito H, et al. Effect of ACE gene on diabetic nephropathy in NIDDM patients with insulin resistance. Am J Kidney Dis. 1999;33:276-281.
39. Kunz R, Bork JP, Fritsche L, et al. Association between the angiotensin-converting enzyme insertion/deletion polymorphism and diabetic nephropathy. A methodologic appraisal and systematic review. J Am Soc Nephrol. 1998;9:1653-1663.
40. Shah VO, Scavini M, Nikolic J, et al. Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J Clin Endocrinol Metab, 1998;83:2886.
41. Bluthner M, Schmidt S, Siffert W, et al. Increased frequency of G-protein b3 subunit 825 T allele in dialyzed patients with type-2 diabetes. Kidney Int. 1999;55:1247-1250.
42. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care. 2002;25:134-147.
43. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(Suppl 1):S80-S82.
44. Earle K, Viberti GC. Familial, hemodynamic, and metabolic factors in the predisposition to diabetic kidney disease. Kidney Int. 1994;45:434-437.
45. Ismail N, Becker B, Strzelczyk P, et al. Renal disease and hypertension in noninsulin-dependent diabetes melutus. Kidney Int. 1999;55:1-28.
46. Nakano S, Fukudu M, Hotta F, et al. Revised circadian rhythm is associated with occurrences of both fatal and nonfatal vascular events in NID-DM subjects. Diabetes, 1998;47:1501-1506.
47. Mogensen CE. Microalbuminuria, blood pressure, and diabetic renal disease: origin and development of ideas. Diabetologia. 1999;42:263-285.
48. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM. 1993;329:977-986.
49. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose contral with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33). Lancet. 1998;352:837-853 [Erratum. Lancet. 1999;354:602].
50. Mulec H, Blohme G, Grandi B, et al. The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant. 1998;13:651-655.
51. Orth SR, Ritz E, Schrier RW. The renal risk of smoking. Kidney Int. 1997;51:1669-1677.
52. Stegmayr BG. A study of patients with diabetes mellitus (type-1) and end-stage renal failure: tobacco use may increase risk of nephropathy and death. J Intern Med. 1990;228:121-124.
53. Biesenbach G, Zazgornik J. Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. Diabetes Care. 1996;19:635-638.
54. Klein R, Klein BEK, Moss SE, et al. The 10-year incidence of renal insufficiency in people with type-1 diabetes. Diabetes Care. 1999;22:743-751.
55. The DCCT Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;47:1702-1720.
56. The DCCT/EDIC Research Group. Retinopathy and nephropathy in patients with type-1 diabetes four years after a trial of intensive therapy. NEJM. 2000;342:381-389.
57. The DCCT/EDIC Research Group. Effect of Intensive therapy on the microvascular complications of type-1 diabetes mellitus. JAMA. 2002;287:2563-2569.
58. Okhubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin-dependent diabetes mellitus: a randomized prospective six-year study. Diabetes Res Clin Prac. 1995;28:103-117.
59. Standards of medical care for patients with diabetes mellitus (Position Statement). Clinical Practice Recommendations 2001. Diabetes Care. 2001;24(suppl 1):S33-S43.
60. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type-2 diabetes. J Human Hypertens. 2003;17:7-12.
61. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646-661.
62. Mailloux LU, Levey AS. Hypertension in chronic renal disease. Am J Kidney Dis. 1998;32(Suppl 3):S120-S141.
63. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study; Ann Intern Med. 1995;123:754-762.
64. Parving HH, Andersen AR, Smidt UM. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983;1:1175-1179.
65. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. An update. Hypertension. 2001;37:1053.
66. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) Report. JAMA. 2002;289:2560-2571.
67. Lazarus JM, Bourgoignie JJ, Buckalew Jr VM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. Modification of Diet in Renal Disease Study. Hypertension. 1997;27:347-354.
68. Muirhead N, Feegan BF, Mahon J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type-2 diabetes mellitus: a placebo-controlled trial. Current Therapeutic Research. 1999;60:650-660.
69. Lewis EJ, Hunsicker LG, Clarke WR, et al. for the Collaborative Group. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in patients with nephropathy due to type-2 diabetes. NEJM. 2001;345:851-860.
70. Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction with VAL-sartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type-2 diabetes mellitus. Circulation. 2002;106:672-678.
71. Heart Outcome Prevention Evaluation Study Investigators. Effect of ramipri! on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, 2000;355:253-259. [Erratum, Lancet. 2000;356:860].
72. Brenner BM, Cooper ME, de Zeeuw D, et al. for the RENAAL Study Investigotors. Effects of losortan on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy. NEJM. 2001;345:861-869.
73. United Kingdom Prospective Diabetes Group: efficacy of atenolol and captopril in reducing the risk of macrovascular and microvascular complications in type-2 diabetes;UKPDS 39. BMJ. 1998;317:713-720.
74. United Kingdom Prospective Diabetes Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type-2 diabetes. UKPDS 38. BMJ. 1998;317:703-713.
75. Goldstein S. Beta blockers in hypertensive and coronary heart disease. Arch Inten Med. 1996;156:1267-1276.
76. Sawicki PT, Siebenhofer A. Beta-blocker treatment in diabetes mellitus. J Intern Med. 2001;250:11-17.
77. Bakris GL, Mangrum A, Copley JB, et al. Effect of calcium channel or beta blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997;29:744-750.
78. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990;112:707-708.
79. Bakris GL, Coopley JB, Vicknar N, et al. Calcium channel blockers versus other antihypertensive drugs on progression of NIDDM-associated nephropathy. Kidney Int. 1996;50:1641-1650.
80. Melbourne Diabetic Nephropathy Study Group, Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ. 1991;302:210-216.
81. Vellussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996;45:216-222.
82. Salako BL, Finomo FO, Kadiri S, et al. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type-2 diabetic nephropathy. Afr J Med Med Sci. 2002;31:53-57.
83. Rosssing P, Tarnow L, Boelskifte S, et al. Differences between nisoldipine and lisinopri! on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes. 1997;46:481-487.
84. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276:1886-1892.
85. Mogensen CE, Neldam S, Tikkenen I, et al. Randomized control trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin-dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study.BMJ. 2000;321:1440-1444.
86. Jacobson P, Andersen S, Jensen BR, et al. Additive effect of ACE inhibition and angiotensin-II receptor blockade in type-1 diabetic patients with diabetic nephropathy. J Am Soc Nephrol. 2003;14:992-999.
87. Rossing K, Christensen PK, Jensen BR, et al. Dual blockade of the renin angiotensin system in diabetic nephropathy. A randomized double-blind crossover study. Diabetes Care. 2002;25:95-100.
88. Rosner MH, Okusa MD. Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonist in the treatment of patients with type-2 diabetes mellitus. Arch Intern Med. 2003;163:1025-1029.
89. Ritz E, Ogata H, Orth SR. Smoking: a factor promoting onset and progression of diabetic nephropathy. Diabetes Metab. 2000;26(Suppl 4):54-63.
90. Levey AS, Adlas S, Caggiula AN, et al. Effects of dietary protein restriction on the progression of advanced renal disease in the modification of diet in renal disease study. Am J Kidney Dis. 1996;27:652-663.
91. Klahr S. Is there a role for a diet very low in protein with or without supplements in the management of patients with end-stage renal disease? Curr Opin Nephrol Hypertens. 1996;5:384-387.
92. Zeller K, Whittaker E, Sullivan L, et al. Effect of dietary protein restriction on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1991;324:78-84.
93. Hansen AP, Tauber-Lassen E, Jensen BR, et al. Effect of dietary protein restriction on prognosis in type-1 diabetic patients with diabetic nephropathy. Presented at the European Diabetic Nephropathy Study Group. 14th Annual Meeting, County Durban, United Kingdom, May 2001, abstract.
94. NKF-K/DOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Am J Kidney Dis. 2002;35:S1-S140.
95. Krolewski AS, Warram JHG, Christlies AR, Hypercholesterolemia-A determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int. 1994;Suppl 45:S125-S131.
96. Lam KSL, Cheing IKP, Jamis ED, et al. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia. 1995;38:604-609.
97. Fried LF, Orchard TJ, Kasiske BL. The effect of lipid reduction on renal disease progression. A meta-analysis. Kidney Int. 2001;59:260-269.
98. Graede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type-2 diabetes mellitus and microalbuminuria: the steno type-2 randomized study. Lancet. 1999;353:617-622.
99. Zoja C, Corna D, Camozzi D, et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol. 2002;13:2898-2908.
100. Gambaro G, Cavazzana AO, Lazi P, et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int. 1992;42:285-291.
101. Solini A, Vergnani L, Ricci F, et al. Glycosaminoglycans delay the progression of nephropathy in NiDDM. Diabetes Care. 1997;13:539-545.
102. Gambaro G, Kinalska C, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type-1 and type-2 diabetic patients. The Di. NAS randomized trial. J Am Soc Nephrol. 2002;13:1615-1625.
103. Gokal R, Mallick NP. Peritoneal dialysis. Lancet. 1999;353:823-828.
104. Gudex G. Health-related quality of life in end-stage renal failure. Qual Life Res. 1995;4:359-366.
105. Tzamaloukas AH. Diabetes. In: Handbook of Dialysis, 2nd Ed. Daugirdus JT, Ing TS, eds. Little Brownard. 1994 pp. 422-432.
106. Mailloux LU. Dialysis in diabetic nephropathy. UpToDate 2000, Version 8.1.
107. Mallick NP, Gokal R. Hemodialysis. Lancet. 1999;353:737-742.
108. Collins AJ. How can the mortality rate of chronic dialysis patients be reduced. Semin Dial. 1993;6:102.
109. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. NEJM. 1999;341:1725-1729.
110. Robertson RP. Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus. UpToDate 2000. Version 8.1.
111. Humar A, Johnson EM, Gillingham KJ, et al. Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis. Transplantation. 1998;65:229.
112. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type-2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose. N Engl J Med. 2001;344:1343-1350.
113. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study. Diabetes Care. 1997;20:537-544.
114. Diabetes Prevention Research Group. Reduction in the incidence of type-2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
115. Stewart KJ. Exercise training and the cardiovascular consequences of type-2 diabetes and hypertension. Plausible mechanisms for improving cardiovascular health. JAMA. 2002;288:1622-1631.
116. The prevention or delay of type-2 diabetes. Position Statement. Diabetes Care. 2003;26:S62-S69.
117. Healthy People 2010. Available at http://www.healthy people.gov/document/ HTML/Volume 1/04Chronic Kidney Disease.htm. Accessed on April 6, 2004.